Role of IL-1β in type 2 diabetes

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 17, Issue 4, 2010, Pages 314-321

  Dinarello, Charles A ^a,b   Donath, Marc Y ^c   Mandrup Poulsen, Thomas ^d,e,f  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d HAGEDORN RESEARCH INSTITUTE   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

adipocyte; caspase 1; cytokines; inflammasome; inflammation

Indexed keywords

CANAKINUMAB; FATTY ACID; GLUCOSE; INFLAMMASOME; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; LEPTIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADIPOCYTE; AUTOINFLAMMATORY DISEASE; CARDIOVASCULAR DISEASE; CELL DEATH; CELL DIFFERENTIATION; CINCA SYNDROME; CYTOKINE PRODUCTION; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET; REVIEW; ANIMAL; BIOLOGICAL MODEL; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; ISLETS OF LANGERHANS; MODELS, BIOLOGICAL;

EID: 77955770771     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32833bf6dc     Document Type: Review

References (44)

1. Donath MY, Boni-Schnetzler M, Ellingsgaard H, Ehses JA. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology (Bethesda) 2009; 24:325-331. A recent review of the topic.
2. Boni-Schnetzler M, Boller S, Debray S, et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin- 1 receptor I. Endocrinology 2009; 150:5218-5229.
3. Boni-Schnetzler M, Thorne J, Parnaud G, et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta-cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab 2008; 93:4065-4074.
4. Maedler K, Sergeev P, Ehses JA, et al. Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci USA 2004; 101:8138-8143.
5. Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL- 1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110:851-860.
6. Chen J, Saxena G, Mungrue IN, et al. Thioredoxin-interacting protein: a critical link between glucose toxicity and beta-cell apoptosis. Diabetes 2008; 57:938-944.
7. Shalev A, Pise-Masison CA, Radonovich M, et al. Oligonucleotide microarray analysis of intact human pancreatic islets: identification of glucose-responsive genes and a highly regulated TGFbeta signaling pathway. Endocrinology 2002; 143:3695-3698.
8. Koenen TB, Stienstra R, van Tits LJH, et al. Txnip expression associates with hyperglycemia-induced inflammation in human peripheral blood mononuclear cells and adipocytes. Diabetologia 2009; 52 (Suppl):253.
9. Robertson RP, Harmon J, Tran PO, Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004; 53 (Suppl 1):S119-S124.
10. Zhou R, Tardivel A, Thorens B, et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010; 11:136-140.
11. Dinarello CA, Ikejima T, Warner SJ, et al. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol 1987; 139:1902-1910.
12. Toda Y, Tsukada J, Misago M, et al. Autocrine induction of the human pro-IL- 1beta gene promoter by IL-1beta in monocytes. J Immunol 2002; 168:1984-1991.
13. Dinarello CA. Anti-inflammatory agents: present and future. Cell 2010; 140:935-950.
14. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Ann Rev Immunol 2009; 27:519-550.
15. Ehses JA, Perren A, Eppler E, et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 2007; 56:2356-2370.
16. Ehses JA, Lacraz G, Giroix MH, et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci USA 2009; 106:13998-14003.
17. Weksler-Zangen S, Raz I, Lenzen S, et al. Impaired glucose-stimulated insulin secretion is coupled with exocrine pancreatic lesions in the Cohen diabetic rat. Diabetes 2008; 57:279-287.
18. Mandrup-Poulsen T, Bendtzen K, Nerup J, et al. Affinity-purified human interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia 1986; 29:63-67.
19. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356:1517-1526.
20. Gattorno M, Tassi S, Carta S, et al. Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum 2007; 56:3138-3148.
21. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360:2416-2425.
22. Reddy S, Jia S, Geoffrey R, et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med 2009; 360: 2438-2444.
23. Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360:2426-2437.
24. Dinarello CA. Interleukin-1beta and the autoinflammatory diseases. N Engl J Med 2009; 360:2467-2470.
25. Lamacchia C, Palmer G, Seemayer CA, et al. Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cellspecific interleukin-1 receptor antagonist. Arthritis Rheum 2010; 62:452-462.
26. Maedler K, Storling J, Sturis J, et al. Glucose- and interleukin-1beta- induced beta-cell apoptosis requires Ca2 influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/ inwardly rectifying K channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets. Diabetes 2004; 53:1706-1713.
27. Donath MY, Weder C, Brunner A, et al. XOMA 052, a potential disease modifying anti1L-1beta antibody, shows sustained HbA1c reductions 3 Months after a single injection with no increases in safety parameters in subjects with type 2 diabetes. Diabetes 2009; 58:A30.
28. Larsen CM, Faulenbach M, Vaag A, et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009; 32:1663-1668.
29. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006; 355:581-592.
30. Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201:1479-1486.
31. Lachmann HJ, Lowe P, Felix SD, et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009; 206:1029-1036.
32. Karlsen AE, Pavlovic D, Nielsen K, et al. Interferon-gamma induces interleukin- 1 converting enzyme expression in pancreatic islets by an interferon regulatory factor-1-dependent mechanism. J Clin Endocrinol Metab 2000; 85:830-836.
33. Mandrup-Poulsen T, Wogensen LD, Jensen M, et al. Circulating interleukin-1 receptor antagonist concentrations are increased in adult patients with thermal injury. Crit Care Med 1995; 23:26-33.
34. Wogensen LD, Kolb-Bachofen V, Christensen P, et al. Functional and morphological effects of interleukin-1 beta on the perfused rat pancreas. Diabetologia 1990; 33:15-23.
35. Wogensen LD, Reimers J, Nerup J, et al. Repetitive in vivo treatment with human recombinant interleukin-1 beta modifies beta-cell function in normal rats. Diabetologia 1992; 35:331-339.
36. Reimers JI, Bjerre U, Mandrup-Poulsen T, Nerup J. Interleukin 1 beta induces diabetes and fever in normal rats by nitric oxide via induction of different nitric oxide synthases. Cytokine 1994; 6:512-520.
37. Kolb H, Mandrup-Poulsen T. The global diabetes epidemic as a consequence of lifestyle-induced low-grade inflammation. Diabetologia 2010; 53:10-20.
38. Netea MG, Nold-Petry CA, Nold MF, et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 2009; 113:2324-2335.
39. Schindler R, Clark BD, Dinarello CA. Dissociation between interleukin-1b mRNA and protein synthesis in human peripheral blood mononuclear cells. J Biol Chem 1990; 265:10232-10237.
40. Stienstra R, Joosten LA, Koenen T, et al. The inflammasome-mediated caspase-1 activation controls apipocyte differentiation and insulin sensitivity. Cytokine 2009; 48:134. (abs).
41. Netea MG, Joosten LA, Lewis E, et al. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med 2006; 12:650-656.
42. Zorrilla EP, Sanchez-Alavez M, Sugama S, et al. Interleukin-18 controls energy homeostasis by suppressing appetite and feed efficiency. Proc Natl Acad Sci USA 2007; 104:11097-11102.
43. Zilverschoon GR, Tack CJ, Joosten LA, et al. Interleukin-18 resistance in patients with obesity and type 2 diabetes mellitus. Int J Obes (Lond) 2008; 32:1407-1414.
44. Marculescu R, Endler G, Schillinger M, et al. Interleukin-1 receptor antagonist genotype is associated with coronary atherosclerosis in patients with type 2 diabetes. Diabetes 2002; 51:3582-3585.